14 / 35
Notes:
Page 77
Volume 08
Clinical Pharmacology & Biopharmaceutics
ISSN: 2167-065X
Pharmacology 2019
World Heart Congress 2019
August 19-20, 2019
JOINT EVENT
conferenceseries
.com
August 19-20, 2019 Vienna, Austria
&
7
th
World Heart Congress
24
th
World Congress on
Pharmacology
MicroRNA 103 inhibitor as a potential promising therapeutic target for myocardial infarction
Mai A. Zaafan, Amr M. Abdelhamid, Ayman Selim, Amr Mohamed Alaa, Bana Ammar, Shahd Yehia, Al Hasnaa Abdel Tawwab, Asmaa Esmail, Heba
Abdelhakim
and
Yara Hamdy
October University for Modern Sciences and Arts (MSA), Egypt
M
yocardial infarction (MI) is myocardial cell death due to severe and prolonged ischemia produced from
atherosclerosis-related coronary artery disease. MI triggers a cascade of events and reparative phases end with
myocardial cell necrosis. MicroRNA (miR) is non-coding single stranded RNA that regulates protein expression.
miR-103 is used to regulate expression of Fas-associated death domain (FADD) which decreases necroptosis of
ischemic myocardium. The study aims to investigate the modulatory effect of up-regulating mRNAs translation
processes of myocardial infarction induced with Isoprenaline HCL 100 mg/kg (ISO) by injecting miR-103 inhibitor.
Eighteen mice (15-25 gm) were allocated into three groups; Group A (control) received normal saline, Group B
received ISO and Group C received ISO and miR-103 inhibitor. Mice were sacrificed by cervical dislocation under
urethane anesthesia. Blood and hearts samples were collected for biochemical analysis of miR103, FADD, receptor
interacting protein kinase (RIPK), nuclear factor-kB (NF-kB), tumor necrosis factor-α (TNF-α), interleukine-6 (IL-
6),Troponin-I and creatine kinase-MB (CK-MB). In addition, hearts were used for histopathological examination.
Results showed that administration of miR-103 antagomir leads to increase in FADD protein levels in group C
compared to A and B. While miR-103, RIPK, NF-kB, TNF-α and IL-6 showed high levels of expression in group B
that is attenuated in group C. Troponin-I and CK-MB also supported the previous results. Histopathological test
showed normal histological structure in groups A and C while focal degeneration in myocardium in B. Accordingly,
these results indicate a promising suppression of MI manifestations upon inhibition of miR-103.
Mai A. Zaafan et al., Clin Pharmacol Biopharm, Volume 08